Search

Displaying results 9711 - 9720 of 9904 in total
  1. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). … A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as a

  2. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

  3. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.

  4. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  5. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent

  6. Drug

    Gusperimus

    go.drugbank.com/drugs/DB12692
    Investigational

    Gusperimus has been used in trials studying the treatment of Lupus Nephritis, Wegeners Granulomatosis, and Wegener's Granulomatosis.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.

  8. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    [A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. … [L7901] While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.

  10. Drug

    Pheneticillin

    go.drugbank.com/drugs/DB13337
    Approved

    Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.